Oral pre-exposure prophylaxis (PrEP) may be the next focus of HIV prevention efforts, The New York Times reports. In a few months, results will be made public from oral PrEP trials, in which people who do not have the virus but who regularly engage in high-risk behavior take a daily dose of antiretroviral (ARV) drugs normally taken by people with HIV. If the trials are successful, regulatory authorities may approve pills for oral PrEP faster than ARV-infused vaginal gels, which showed promise in trials last year. The pills have already been found safe and effective for treatment.

To read the Times article, click here.